BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 12737000)

  • 21. Acute injury with intravenous iron and concerns regarding long-term safety.
    Bishu K; Agarwal R
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
    Faich G; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
    Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
    Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous iron therapy: well-tolerated, yet not harmless.
    Sengölge G; Hörl WH; Sunder-Plassmann G
    Eur J Clin Invest; 2005 Dec; 35 Suppl 3():46-51. PubMed ID: 16281958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
    Kaskel FJ
    Nat Clin Pract Nephrol; 2006 May; 2(5):244-5. PubMed ID: 16932433
    [No Abstract]   [Full Text] [Related]  

  • 26. Updating practices in an evolving IV iron and anemia environment: practical solutions.
    Amerling R; Easom A; Juergensen P
    Nephrol Nurs J; 2007; 34(5):533-41; quiz 542-3. PubMed ID: 18041456
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron therapy in chronic kidney disease: current controversies.
    Kovesdy CP; Kalantar-Zadeh K
    J Ren Care; 2009 Dec; 35 Suppl 2():14-24. PubMed ID: 19891681
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
    Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
    J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients.
    Sinha S; Chiu D; Peebles G; Swoboda P; Kolakkat S; Lamerton E; Fenwick S; Bhandari S; Kalra PA
    QJM; 2011 Mar; 104(3):221-30. PubMed ID: 20956457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate.
    Fishbane S; Kowalski EA
    Semin Dial; 2000; 13(6):381-4. PubMed ID: 11130261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products.
    Charytan C; Schwenk MH; Al-Saloum MM; Spinowitz BS
    Nephron Clin Pract; 2004; 96(2):c63-6. PubMed ID: 14988600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Caring for the renal failure patient: optimizing iron therapy.
    Folkert VW; Javier AM; O'Mara NB
    Nephrol Nurs J; 2002 Dec; 29(6):586-93; quiz 594-5. PubMed ID: 12596608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IV iron use in patients with higher serum ferritin: case study on anemia in kidney disease.
    Larson K
    Nephrol Nurs J; 2008; 35(2):184-93; quiz 194-5. PubMed ID: 18472686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementing continuous quality improvement strategies for improving iron replacement in hemodialysis patients.
    Trenkle JA
    Nephrol Nurs J; 2001 Oct; 28(5):561-5. PubMed ID: 12143432
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Iron requirements in hemodialysis.
    Sargent JA; Acchiardo SR
    Blood Purif; 2004; 22(1):112-23. PubMed ID: 14732819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of anemia in chronic kidney disease (predialysis) patients: nephrology nursing implications.
    Wish JB; Weigel KA
    Nephrol Nurs J; 2001 Jun; 28(3):341-5. PubMed ID: 12143456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjusting i.v. iron and EPO doses in patients on hemodialysis prior to continuing surgery: can we protect our patients education from iron-deficiency anemia?
    Deaver K; Bennington L
    Nephrol Nurs J; 2006; 33(4):430-7; quiz 438. PubMed ID: 17002001
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of intravenous iron supplementation in chronic kidney disease: an update.
    Macdougall IC; Geisser P
    Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evolution of iv iron compounds over the last century.
    Macdougall IC
    J Ren Care; 2009 Dec; 35 Suppl 2():8-13. PubMed ID: 19891680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous iron in a primary-care clinic.
    Maslovsky I
    Am J Hematol; 2005 Apr; 78(4):261-4. PubMed ID: 15795917
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.